ABSTRACT
Despite the use of multidrug therapy, leprosy remains endemic in some countries. The association of several human leucocyte antigen (HLA) alleles and gene polymorphisms with leprosy has been demonstrated in many populations, but the major immune contributors associated to the spectrum of leprosy have not been defined yet. In this study, genotyping of HLA-A, -B, -DR, and -DQ alleles was performed in leprosy patients (n = 113) and control subjects (n = 117) from the region with the highest incidence for the disease in México. The odds of developing leprosy and lepromatous subtype were 2.12- and 2.74-fold higher in carriers of HLA-A*28, and 2.48- and 4.14-fold higher for leprosy and dimorphic subtype in carriers of DQB1*06. Interestingly, DQB1*07 was overrepresented in healthy individuals, compared to patients with leprosy (OR = 0.08) and the lepromatous subtype (OR = 0.06). These results suggest that HLA-A*28 is a marker for predisposition to leprosy and the lepromatous subtype and DQB1*06 to leprosy and the dimorphic subtype, while DQB1*07 might be a resistance marker in this Mestizo population.
Subject(s)
HLA Antigens/genetics , Indians, North American/genetics , Leprosy/genetics , Adult , Aged , Alleles , Case-Control Studies , Female , Gene Frequency , Genetic Association Studies , Genetic Markers , Genetic Predisposition to Disease , Humans , Male , Mexico , Middle Aged , Polymorphism, GeneticABSTRACT
La mastocitosis es una enfermedad que se caracteriza por un incremento en el número de mastocitos, que puede aparecer durante la edad pediátrica, clasificándose en dos grandes grupos. El primero está confirmado a la piel (mastocitosis cutánea) y el segundo involucra varios órganos 8mastocitosis sistémica). La mastocitosis cutánea generalmente se cura de manera espontánea a esta edad; sin embargo, debemos vigilar su evolución ante la posibilidad de complicaciones sistémicas. La mastocitosis sistémica es más frecuente en la edad adulta; sus síntomas son resultado de la liberación de mediadores, tales como la histamina, leucotrienos, prostaglandinas y otros. El tratamiento se dirige al control de los síntomas. Se comunican tres casos clínicos vistos en el Hospital infantil de México Federico Gómez, insistiendo en la benignidad de esta afección durante la niñez
